Related Experiment Video
Updated: Jan 29, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
Stefan Zimmerman1, Arundhati Das2, Shuhang Wang3
1Oncology Department, Service of Immuno-Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Abstract:
SCLC remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently programmed death ligand 1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended-disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immunotherapy and targeted therapies based on specific biomarkers and rational combinations. Here we discuss the preclinical and clinical strides in 2017 and 2018 that put us on the threshold of a new era in therapeutics and will, it is hoped, translate into significant improvements in survival.
Insights
New immunotherapies show promise for extensive-stage small cell lung cancer (SCLC). Programmed death ligand 1 inhibition improves chemotherapy efficacy, offering hope for better survival rates in SCLC treatment.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options.
- Standard chemotherapy offers modest survival benefits for SCLC patients.
Observation:
- Recent advancements include immunotherapy and comprehensive genomic profiling.
- Programmed death ligand 1 (PD-L1) inhibition has demonstrated improved efficacy when combined with standard chemotherapy in extended-disease SCLC.
Findings:
- Preclinical and clinical studies from 2017-2018 highlight promising therapeutic strategies.
- Understanding pathway interactions is key to developing tailored treatments.
Implications:
- Emerging targeted therapies and immunotherapies offer new hope for SCLC patients.
- Biomarker-driven approaches and rational drug combinations are expected to significantly improve survival outcomes.
More Related Videos
Related Concept Videos
The Scientific Method
The Scientific Method
Generally, predictions are tested using carefully-designed experiments. Based on the outcome of these...
The Scientific Method
Scientific Laws and Theories
Thoracic Aorta
The Thoracic Cage: Sternum
The sternum is the elongated bony structure on the anterior side of the thoracic cage. It consists of three parts: the manubrium, the body, and the xiphoid...

